We compared acid citrate-dextrose (ACD-B) and heparin to determine which anticoagulant better preserves leukocytes for Iysosomal enzyme assays if processing was done immediately or delayed for 24 h or more. Twenty normal subjects had blood drawn into tubes containing either ACD-B or heparin. The leukocytes were isolated by sedimentation in dextran (50 g/L) <2, 24, 48, and 72 h later. The most apparent difference was that cell counts indicated a 30% reduction in the number of leukocytes for ACD-B and a 95% reduction for hepann-treated cells at 48 h. The neutrophil function assay indicated that leukocyte processing must be done in <24 h regardless of the anticoagulant used, and that heparin is to be preferred. A comparison of hepann and AGO-B for maintenance of the activity of arylsulfatase A (EC 3.2.6.1) and hexosaminidase (EC 3.2.1.50) indicates that there is no effect of anticoagulant. However, at 48 h after venipuncture, there is an 80% reduction in the number of hepann-treated samples that are suitable for use in the assay. Those laboratories doing lysosomal enzyme tests on mailed specimens, which are most often >24 h old, should use ACD-B as anticoagulant.
isolation of leukocytes and their resulting enzyme assays may be delayed for hours, if not days. Various laboratories have chosen either acid citrate-dextrose, type B (ACD-B), or heparin for preservation of whole blood. Therefore, it is important to establish which anticoagulant best preserves enzyme activity. It is also important to maintain consistent normal-range values for all samples tested, particularly because, in genetic disease detection,carriers (50% level) must be readily distinguished from both normal and very low activities. It was apparent from practical experience that the usual anticoagulant, heparin, was unsatisfactory in obtaining a good yield of leukocytes after 24 h and that an overnight delay in harvesting cells caused a dramatic loss of leukocytes.
A variety of parameters were chosen to test for the most suitable anticoagulant. distribution of cells was determined for any quantification differences in the cell types that were being isolated. The neutrophil function assay was used to determine the ability of the phagocytic cells in the leukocyte preparation to function as a phagocyte. We chose two enzyme assays, arylsulfatase A (EC 3.1.6.1) and hexosaminidase (EC 3.2.1.50), on the basis of the number of samples that come to us from outside the institution and because they are representative of leukocyte lysosomal enzyme assays.
MaterIals and Methods

Sample Preparation
Twenty normal subjects had blood drawn in 6-mL ACD-B tubes (Becton Dickinson Vacutainer Systems, Rutherford, NJ 07070) and 5-mL heparin-containing tubes (Venoject; Terumo Medical Corp., Elkton, MD 21921). Three samples with each type of anticoagulant were drawn from all subjects, and a fourth sample with each anticoagulant was drawn from three of these subjects. The whole-blood samples were left at room temperature to simulate expected conditions when sample processing isdelayed. Within less than 2 h, one ACD-B-and one heparin-treatedwhole-blood sample from each subject were processed to isolate leukocytes by sedimentation with dextran (50 g/L) (1). At 24,48, and 72 h, this process was repeated. When the leukocytes were processed, they were immediately counted, smeared on glass slides for differential counts, and the neutrophil-function assay was done. The remaining leukocytes were divided into two pellets and frozen at -20 #{176}C for later assay of arylsulfatase A and hexosaminidase. luminol (Eastman Kodak, Rochester, NY 14650) in dimethyl sulfoxideand 40 mL of GHBSS per liter] in glass scintillation vials with 6.65 ig of zymosan, which had been opsonized at 37#{176}C for 30 mm by pooled human serum. The production of superoxide was measured by a Model 6800 scintillation counter (Beckman Instruments, Fullerton, CA 92634) programmed in the "out of coincidence" mode.
Differential Counts
The distribution of polymorphonuclear and mononuclear cells in the leukocyte preparations was determined by spreading the leukocytes, which had been resuspended in 0.85 mol/L NaC1, over a glass slide and allowing this to air dry. The cells were then stained with Wright's stain, and 100 leukocytes were counted (3). activity at <2 h, 18% more activity at 24 h, and 4% more activity at 48 h, and the activity is more stable over time (Figure 3c ). The increase in the mean (in units per gram) for heparin-treated cells at 48 h probably reflects the 80% reduction in the number of cells.
Assay for Arylsulfatase
Discussion
The choice of anticoagulant, ACD-B or heparin, will be determined by the individual assay, the total number of leukocytes available for assay, and the interval until leukocytes are isolated after the blood specimen is drawn. If the goal is to study the phagocytic ability of leukocytes, then heparin is clearly the anticoagulant of choice, and there can be no delay in processing the cells. If the neutrophil-function assay were delayed, it probably would not be possible to differentiate between diminished cell function of the patient and deterioration of cell function during cell storage.
Arylsulfatase
A and hexosaminidase assays can be done when leukocyte processing is delayed for 48 h. The choice of anticoagulant will make little difference in the results for either arylsulfatase A assay or hexosaminidase assay. The difficulty arises at 48 h with heparin-treated blood, because 80% of the cells are no longer recoverable. Since our laboratory frequently processes 48-h-old samples for leukocyte lysosomal enzyme assays, heparmnis no longer used as the anticoagulant. Cell counts decline over time for both anticoagulants, but the 48-h decrease for ACD-B-treated cells is 30%, while that for heparin-treated cells is 95%. Figure 4 indicates that, at 48 h, heparin-treated erythrocytes have undergone a reduction in density such that most of the erythrocytes will not separate from the leukocytes in dextran (50 g/L) at 1 x g. Heparin is known to be the only physiological anticoagulant and is produced in mast cells. Its action is in combining with antithrombin ifi and neutralizing many liver-dependent clotting factors (6). We have shown here that with no erythrocyte preservative, heparin is probably not the best choice of anticoagulant if erythrocytes are to be stored for longer than 24-48 h, as Heaton has also observed (7) We thank Joyce Freiheit for secretarial assistance.
